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ABSTRACT
Objective: Pyrimidine heterocycles possessing hydroxy group has a unique place in medicinal chemistry and also plays a key role in biological processes. 
In the biological functions at cellular level pyrimidine plays imperative roles which lead the researchers to design a variety of its derivatives. The aim 
of the present study was to synthesize the novel set of 4-(4-fluoro-3-methylphenyl)-6-(substituted aryl)-1,6-dihydropyrimidin-2-ol derivatives. These 
compounds were screened for their analgesic and anti-inflammatory activities.
Methods: A novel series of 4-(4-fluoro-3-methylphenyl)-6-(substituted aryl)-1,6-dihydro pyrimidin-2-ol derivatives were furnished in two steps 
starting from 4-fluoro-3-methyl acetophenone through chalcone formation. Human red blood cell membrane stabilization method and carrageenan-
induced rat paw edema test were performed for screening in vitro and in vivo anti-inflammatory activity, respectively. Tail-flick technique was 
performed for screening analgesic activity.
Results: All the synthesized 4-(4-fluoro-3-methylphenyl)-6-(substituted aryl)-1,6-dihydro pyrimidin-2-ol derivatives were characterized by Fourier-
transform infrared spectroscopy,1H nuclear magnetic resonance, mass spectroscopy, and bases of elemental analysis. The result of biological screening 
revealed that many of the new derivatives were endowed with improved anti-inflammatory and analgesic activities.
Conclusion: Nature of the substituent played a major role in anti-inflammatory and analgesic activities. The pyrimidine derivative with chlorophenyl 
substitution exhibited potent anti-inflammatory and analgesic activities. From the results, it was concluded that 6-(4-chlorophenyl)-4-(4-fluoro-3-
methyl phenyl)-1,6-dihydropyrimidin-2-ol was the most active compound.
Keywords: Pyrimidine, Chalcone, Anti-inflammatory, Analgesic, Carrageenan, Acetic acid.
INTRODUCTION
Pyrimidine is ubiquitous in nature and found in a large group of 
biologically active compounds such as nucleic acids, vitamins, and 
coenzymes. They play a key role in the human physiological process. 
Pyrimidine [1] is a six-membered heterocycle with two nitrogen 
atoms situated in a 1,3-arrangement. The other name of pyrimidine is 
m-diazine or 1,3-diazine. Both nitrogen atoms in pyrimidines resemble 
pyridine nitrogen. The aromatic ring consists of a lone pair of electrons 
in the sp2 hybrid orbital which belongs to the nitrogen atoms in its 
plane. These lone pairs are not needed for aromatic sextet; hence, they 
are basic in nature similar to pyridine. In the biological functions at 
cellular level pyrimidine plays a key role, which leads the researchers to 
design a variety of its derivatives. Pyrimidine heterocycles possessing 
hydroxyl group have a unique place in medicinal chemistry [2] and 
also plays a key role in biological processes [3]. The pharmacologically 
active drugs, namely barbituric acid and its several derivatives 
(e.g., Veranal) (Fig. 1) possess pyrimidine moiety in its main nucleus [4]. 
Pyrimidine derivatives provide a variety of biological activities such as 
cytotoxic [5], antimalarial [6], antioxidant [7], tyrosinase inhibitory [8], 
anti-inflammatory [9], cyclin-dependant kinase inhibitors [10], alopecia 
agent [11], and antibacterial [12].
The inflammation process involves a cascade that can be elicited by 
numerous stimuli (e.g. infectious agents, ischemia, and antigen-antibody 
interaction). Nonsteroidal anti-inflammatory drugs (NSAIDs) represent 
a heterogeneous family of pharmacologically potent compounds used 
to alleviate acute and chronic inflammation, pain, and fever. Almost two 
decades ago, steroidal drugs, namely prednisolone, dexamethasone, 
and betamthansone were considered to be the choicest and effective 
anti-inflammatory drugs. The serious and enormous adverse effects 
caused by either short-term or long-term usage of steroid therapy 
necessitated accelerated research toward the development of NSAIDs 
since the past two decades [13,14]. In the past decade, copious 
enhances have taken place in the understanding of pathogenesis, and 
as a result, momentous progress has been made and is still being 
made in the development of flawless NSAIDs [15]. Motivated by the 
aforesaid findings, and pursuing our studies on pyrimidine moiety, a 
new series of 4-(4-fluoro-3-methylphenyl)-6-(substituted aryl)-1,6-
dihydropyrimidin-2-ol derivatives were synthesized and tested for 
their anti-inflammatory and analgesic activities.
METHODS
Chemicals and reagents
The chemicals and reagents used in this work were obtained from 
various chemical units Avra, Sigma-Aldrich, SRL and SD Fine Chem. 
The solvents used were of LR grade and purified before their use. 
The silica gel G used for analytical chromatography (thin-layer 
chromatography [TLC]) was obtained from E. Merck India Ltd. Solvent 
systems used were n-hexane:acetone (7:3).
Instruments
All the melting points were taken in open glass capillary and are 
uncorrected. 1H nuclear magnetic resonance (NMR) spectra were taken 
on a Bruker ultra shield (400 MHz) NMR spectrometer in CDCl3 using 
tetramethylsilane [(CH3)4Si] as the internal standard. Chemical shift 
(δ) are expressed in ppm. Mass spectra were obtained on a JEOL-SX-102 
instrument using electron impact ionization. All the IR spectra were 
recorded in KBr pellets on a Jasco Fourier-transform infrared (FT-IR) 
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410 spectrometer. Elemental analyses were performed on a Perkin 
Elmer model 240c analyzer and were within ±0.4% of the theoretical 
values.
Animals
The animals were maintained in colony cages at 25±2°C, relative 
humidity of 45–55%, under a 12 h light and dark cycle and were fed 
standard animal feed [16]. All the animals were acclimatized for a week 
before use. The synthesized compounds were evaluated for their anti-
inflammatory and analgesic activities.
Experimental work
Preparation of (E)-1-(4-fluoro-3-methylphenyl)-3-(substituted 
aryl)prop-2-en-1-one (1a-1i)
The key intermediates (E)-1-(4-fluoro-3-methylphenyl)-3-(substituted 
aryl) prop-2-en-1-one (1a-1i) were prepared according to the reported 
literature [17]. The starting material 4-fluoro-3-methyl acetophenone 
(0.02 mol) was treated with aromatic aldehydes (0.02 mol) in the 
presence of catalytic amount of lithium hydroxide. Ethanol (20 ml) 
was used as a solvent. The reaction mixture was kept for constant 
stirring using a multistage magnetic stirrer at room temperature 
until the solution turns turbid. The reaction was monitored by TLC 
(n-hexane:acetone – 7:3). Then, the reaction mixture was poured into 
crushed ice and neutralized with the help of dil.HCl. The precipitate was 
filtered under vacuum, washed with cold ethanol and distilled water. 
The obtained chalcones were purified by recrystallization and column 
chromatography.
1a (E)-1-(4-fluoro-3-methylphenyl)-3-(thiophen-2-yl) prop-2-en-1-one
Greenish yellow crystals (EtOH), yield = 81%; m.p. 101–103°C. FT-
IR (KBr) cm−1: 1657 (C=O, chalcone), 1585 (C=C), 1149 (C-F), 2949 
(C-CH3), 1HNMR (400 MHz, CDCl3, δ ppm): 2.358(s, 3H, CH3), 7.430 (d, 
1H, α-H), 7.921 (d, 1H, β-H), 7.42 (s, 1H, Ar-H), 7.32 (d, 1H, Ar-H), 7.848 
(d, 1H, Ar-H), 7.86 (d, 1H, Ar-H), 7.433 (d, 1H, Ar-H), 7.972 (s, 1H, Ar-H). 
MS (EI) m/z: 247 (M+). Anal. calcd for C14H11FOS: C, 68.27; H, 4.50; F, 
7.71; O, 6.50; S, 13.02.
1b (E)-3-(2-bromophenyl)-1-(4-fluoro-3-methylphenyl) prop-2-en-1-one
Yellow crystals (EtOH), yield = 76%; m.p. 100–102°C. FT-IR (KBr) 
cm−1: 1658 (C=O, chalcone), 1588 (C=C), 2924 (C-CH3), 1153(C-F), 752.9 
(C-Br). 1HNMR (400 MHz, CDCl3, δ ppm): 2.384 (s, 3H, -CH3), 7.374 (d, 1H, 
α-H), 8.155 (d, 1H, β-H), 7.119-7.93 (d, 7H, Ar-H). MS (EI) m/z: 319 (M+). 
Anal. calcd for C16H12BrFO: C, 60.21; H, 3.79; F, 5.95; O, 5.01; Br, 25.04.
1c (E)-1-(4-fluoro-3-methylphenyl)-3-(2-nitrophenyl) prop-2-en-1-one
Orange crystals (EtOH), yield = 77%; m.p. 94–96°C. FT-IR (KBr) cm−1: 
1674 (C=O, chalcone), 1513(C=C), 2878 (C-CH3), 1292 (C-F), 1341 
(C-NO2).1HNMR(400 MHz, CDCl3, δ ppm): 2.39 (s, 3H, CH3), 7.86 (d, 1H, 
α-H), 8.09 (d, 1H, β-H), 7.585 (s, 1H, Ar-H), 7.173 (d, 1H, Ar-H), 7.71 (d, 
1H, Ar-H) 8.15 (s, 1H, Ar-H), 8.112 (d, 1H, Ar-H), 7.582 (d, 1H, Ar-H), 
7.928 (d, Ar-H). MS (EI) m/z: 284 (M+). Anal. calcd for C16H12FNO3: C, 
67.36; H, 4.24; F, 6.66; N, 4.91;O,16.83.
1d (E)-1-(4-fluoro-3-methylphenyl)-3-(4-hydroxy-3-methoxy-5-nitro 
phenyl)prop-2-en-1-one
Pale yellow crystals (EtOH), yield = 78%; m.p. 91–93°C. FT-IR (KBr) cm−1: 
1684 (C=O, chalcone), 1546 (C=C), 2944 (C-CH3), 1103 (C-F), 1230 
(C-OCH3), 1366 (NO2), 3200 (OH).1HNMR (400 MHz, CDCl3, δ ppm) 
CH3: 2.186 (s, 3H, CH3), 1.727 (s, 1H, OH) 4.043 (s, 3H, -OCH3), 7.664 (d, 1H, 
α-H), 8.245 (d, 1H, β-H), 7.285-8.245(m, 5H, Ar-H). MS (EI) m/z: 331.09 
(M+). Anal. calcd for C17H14NO5: C, 61.63; H, 4.26; F, 5.73; N, 4.23; O, 24.15.
1e (E)-3-(3,4-dimethoxyphenyl)-1-(4-fluoro-3-methylphenyl)prop-2-
en-1-one
Lemon yellow crystals (EtOH), yield = 81%; m.p. 85–87°C. FT-IR 
(KBr) cm−1: 1656 (C=O, chalcone), 1583(C=C), 2930 (C-CH3), 1254(C-F), 
1142 (C-OCH3). 1HNMR(400 MHz, CDCl3, δ ppm): 2.35 (s, 3H, CH3), 
3.936 (d, 6H, -OCH3), 7.739 (d, 1H, α-H), 7.905 (d, 1H, β-H), 7.38 (s, 1H, 
Ar-H), 7.25 (d, 1H, Ar-H), 7.864 (d, 1H, Ar-H), 7.23 (s, 1H, Ar-H), 7.080 
(d, 1H, Ar-H), 6.913 (d, 1H, Ar-H). MS (EI) m/z: 301 (M+). Anal. calcd for 
C18H17FO3: C, 71.99; H, 5.71; F, 6.33; O, 15.98.
1f (E)-3-(4-(dimethylamino)phenyl)-1-(4-fluoro-3-methylphenyl) prop 
-2-en-1-one
Bright red crystals (EtOH), yield = 83%; m.p. 93–95°C. FT-IR (KBr) cm−1: 
1651 (C=O, chalcone), 1593(C=C), 2923 (C-CH3), 1243(C-F). 1HNMR(400 
MHz, CDCl3, δ ppm): 2.37 (s, 3H, CH3), 3.06 (s, 6H, N(CH3), 7.913 (d, 1H, 
α-H), 7.577 (d, 1H, β-H), 7.34 (s, 1H, Ar-H), 7.03 (d, 1H, Ar-H), 7.849 (d, 
1H, Ar-H), 7.78 (s, 2H, Ar-H), 6.734 (d, 2H, Ar-H). MS (EI) m/z: 284 (M+). 
Anal. calcd for C18H18FNO: C, 76.30; H, 6.40; F, 6.71; O, 5.65; N, 4.94.
1g (E)-3-(4-chlorophenyl)-1-(4-fluoro-3-methylphenyl) prop-2-en-1-one
Lemon yellow crystals (EtOH), yield = 77%; m.p. 101–103°C. FT-IR 
(KBr) cm−1: 1663 (C=O, chalcone), 1591(C=C), 2960 (C-CH3), 1243(C-
F), 819 (C-Cl). 1HNMR(400 MHz, CDCl3, δ ppm): 2,38 (s, 3H, CH3), 7,591 
(d, 1H, α-H), 7,93 (d, 1H, β-H), 7,58 (s, 1H, Ar-H), 7,433 (d, 1H, Ar-H), 7,61 
(d, 1H, Ar-H), 7,60 (s, 1H, Ar-H), 7,75 (d, 1H, Ar-H), 7,47 (d, 1H, Ar-H). 
MS (EI) m/z: 275 (M+). Anal. calcd for C16H12ClFO: C, 69.95; H, 4.40; Cl, 
12.91; F, 6.92; O, 5.82.
1h (E)-3-(anthracen-9-yl)-1-(4-fluoro-3-methylphenyl) prop-2-en-1-one
Orange crystals (EtOH), yield = 79%; m.p. 91–93°C. FT-IR (KBr) cm−1: 
1658 (C=O, chalcone), 1591(C=C), 2924 (C-CH3), 1261 (C-F). 1HNMR(400 
MHz, CDCl3, δ ppm): 2.376 (s, 3H, CH3), 7.558 (d, 1H, α-H), 7.964 
(d, 1H, β-H), 7.602 (s, 1H, Ar-H), 7.964 (d, 1H, Ar-H), 7.37 (d, 1H, Ar-H), 
7.43-9.03 (m, 9H, Anthracene-H). MS (EI) m/z: 340 (M+). Anal. calcd for 
C24H17FO: C, 84.68; H, 5.03; F, 5.58; O, 4.70.
1i (E)-3-(5-bromo-2-hydroxy-3-methoxyphenyl)-1-(4-fluoro-3-methyl 
phenyl)prop-2-en-1- one
Orange crystals (EtOH), yield = 69%; m.p. 93–95°C, FT-IR (KBr) cm−1: 
1656 (C=O, chalcone), 1581(C=C), 2923 (C-CH3), 1195 (C-F), C-OH 
(3243), C-OCH3 (1255), C-Br (705): 1HNMR(400 MHz, CDCl3, δ ppm): 
1,617 (s, 3H, CH3), 7,34 (d, 1H, α-H), 9,879 (s, 1H, β-H), 7,203 (d, 5H, 
Ar-H), 7,285(s, 1H, OH), 3,943(s, 3H, C-OCH3): MS (EI) m/z: 365 (M+): 
Anal. calcd for C17H14FBrO3: C, 55.91; H, 3.83; Br, 21.88; F, 5.20; O, 13.14.
Synthesis of 4-(4-fluoro-3-methylphenyl)-6-(substituted aryl)-
1,6-dihydropyrimidin-2-ol. (2a–2i)
The mixture of chalcones (0.002 mol), urea (0.002 mol), and 5ml of 
HCl in absolute ethanol (20 ml) was refluxed on a water bath for 6–8 h. 
The reaction was monitored by TLC. After completion of the reaction, 
40% ammonia was added to neutralize the reaction mixture. The 
reaction mixture was kept in the refrigerator for 2 h. The precipitate 
obtained was filtered under vacuum and recrystallized using ethanol 




Yield 75%, m.p. 168°C, FT-IR (KBr) cm−1: 1041.13 (C-F); 2918.24 














Fig. 1: (a and b) Hypnotic drugs with pyrimidine nucleus
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3449.10 (NH str); 1HNMR(400 MHz, CDCl3, δ ppm) 2.388 (s, 3H, CH3); 
1.593 (m, 1H, N-H); 2.194 (d, 1H, C6’-H pyrimidine); 7.112 (d, 1H, C5’-H 
pyrimidine); 7.134 (m, 2H, C5 and C2-H); 7.125 (d, J=5.2 Hz, 1H, C6-H); 
7.304 (d, J=7.6Hz, 1H, C3’-H); 7.397 (d, J= 3.7 1H, C4’¬-H): MS (EI) m/z: 
288 (M+). Anal. calcd for C15H13FN2OS; C, 62.48; H, 4.54; F, 6.59; N, 9.72; 
O, 5.55; S, 11.12.
2b 4-(4-fluoro-3-methylphenyl)-6-(2-bromophenyl)-1,6-dihydropyrim 
idin-2-ol
Yield 69%, m.p. 154°C, FT-IR (KBr) cm−1:934.23 (C-F); 2924 (C-CH3 Str); 
753 (C-Br); 3050 (Ar C-H str); 1662 (C=N str); 1588 (Ar C=C); 3624 (OH): 
1HNMR(400 MHz, CDCl3, δ ppm) 2.388 (s, 3H, CH3); 1.640 (s, 1H, N-H); 
2.192 (d, J=2Hz, 1H, C6’-H pyrimidine); 7.119 (d, 1H, C5’-H pyrimidine); 
7.163 (m, 2H, C5 and C2-H); 7.425 (m, 1H, C6-H); 7.141–8.153 (m, 4H, 
Ar-H): MS (EI) m/z: 360 (M+). Anal. calcd for C17H14BrFN2O; C, 56.53; H, 
3.91; Br, 22.12; F,5.26; N, 7.76; O, 4.43.
2c 4-(4-fluoro-3-methylphenyl)-6-(2-nitrophenyl)-1,6-dihydropyrimi 
dine-2-ol
Yield 79%, m.p. 162°C, FT-IR (KBr) cm−1: 1029.45 (C-F); 2927.46 
(C-CH3 Str); 3073.32 (Ar C-H str); 1669.54 (C=N str); 1511 (Ar C=C); 1340 
(NO2): 1HNMR(400 MHz, CDCl3, δ ppm) 2.394 (s, 3H, CH3); 2.193 (m, 
1H, N-H); 3.519 (d, J=1.6Hz, 1H, C6’-H pyrimidine); 7.173 (d, 1H, C5’-H 
pyrimidine); 7.269 (m, 1H, C5-H); 7.308 (m, 1H, C5-H); 7.544 (m, 1H, 
C6-H); 7.51 (m, 1H, C4”-H); 7.94 (m, 1H, C3”-H); 7.867 (m, 1H, C6”-H); 
8.152 (m, 1H, C3”-H): MS (EI) m/z: 327 (M+). Anal. calcd for C17H14FN3O3; 
C, 62.38; H, 4.13; F, 5.08; N, 12.84; O, 14.66.
2d 4-(4-fluoro-3-methylphenyl)-6-(4-hydroxy-3-methoxy-5-nitrophen 
yl)-1,6-dihydro pyrimidine-2-ol
Yield 71%, m.p. 172°C, FT-IR (KBr) cm−1: 1044.45 (C-F); 2921.34 (C-CH3 
Str); 3076.17 (Ar C-H str); 1610.70 (C=N str); 1546 (Ar C=C); 3403.75 
(NH str); 3735 (OH); 1463 (NO2); 1269 (OCH3): 1HNMR(400 MHz, CDCl3, 
δ ppm) 2.193 (s, 3H, CH3); 1.606 (s, 1H, O-H); 11.273 (m, 1H, N-H); 
3.518 (d, J=4.8Hz, 1H, C6’-H pyrimidine); 4.051 (s, 3H, OCH3); 7.128 
(m, 3H, C2, C5, C5’-H); 7.673 (m, 1H, C6-H); 8.253 (m, 2H, C2”-H and C6”-H): MS 
(EI) m/z: 373 (M+). Anal. calcd for C17H14FN3O3; C, 62.38; H, 4.13; F,5.08; 
N, 12.84; O, 14.66
2e 6-(3,4-dimethoxyphenyl)-4-(4-fluoro-3-methylphenyl)-1,6-dihydro 
pyrimidine-2-ol
Yield 66%, m.p. 144°C, FT-IR (KBr) cm−1: 1023.84 (C-F); 2932.06 (C-CH3 
Str); 3075.07 (Ar C-H str); 1657.22 (C=N str); 1583 (Ar C=C); 3611 
(OH); 1256 and 1142 (OCH3): 1HNMR (400 MHz, CDCl3, δ ppm) 2.387 
(s, 3H, CH3); 1.641 (s, 1H, O-H); 2.192 (m, 1H, N-H); 3.515 (d, J=4.8Hz, 
1H, C6’-H pyrimidine); 3.981 (d, J=8Hz, 6H, OCH3); 6.941 (d, J=8.4Hz, 1H, 
C5’-H pyrimidine); 7.184 (m, 1H, C2-H); 7.154 (m, 1H, C5-H); 7.394 (m, 
1H, C6-H); 7.761-7.924 (m, 3H, C2”-H, C5”-H and C6”-H): MS (EI) m/z: 342 




Yield 82%, m.p. 158°C, FT-IR (KBr) cm−1: 1053.59 (C-F); 2919.47 (C-CH3 
Str); 3434.74 (Ar NH str); 1648.76 (C=N str); 1594 (Ar C=C); 1299.42 
(C-N str) 1HNMR(400 MHz, CDCl3, δ ppm) 2.378 (s, 3H, CH3); 1.597 (s, 1H, 
O-H); 2.194 (m, 1H, N-H); 3.075 (s, 6H, N-(CH3)2); 3.521 (d, J=5.6Hz, 
1H, C6’-H pyrimidine); 6.734 (d, J=5.2Hz, 1H, C5’-H pyrimidine); 7.133 
(m, 1H, C2-H); 7.342 (m, 1H, C5-H); 7.586 (m, 1H, C6-H); 7.544-7.913 
(m, 4H, C2”-H, C5”-H and C6”-H): MS (EI) m/z: 325 (M+). Anal. calcd for 
C19H20FN3O4; C, 70.13; H, 6.20; F, 5.84; N, 12.19; O, 4.92.
2g 6-(4-chlorophenyl)-4-(4-fluoro-3-methylphenyl)-1,6-dihydropyrimi 
dine-2-ol
Yield 84%, m.p. 166°C, FT-IR (KBr) cm−1:983.19 (C-F); 2924.18 (C-CH3 
Str); 819.23 (C-Cl); 3053.32 (Ar C-H str); 1662.57 (C=N str); 1592 (Ar 
C=C); 3246.75 (NH str); 3433 (OH): 1HNMR(400 MHz, CDCl3, δ ppm) 2.377 
(s, 3H, CH3); 1.771 (s, 1H, O-H); 1.740 (m, 1H, N-H); 2.188 (d, J=1.2Hz, 
1H, C6’-H pyrimidine); 7.150 (m, J=8.4Hz, 1H, C5’-H pyrimidine); 
7.403 (m, 2H, C2”-H and C6”-H); 7.603 (m, 2H, C3”-H and C5”-H); 7.508-
7.922 (m, 4H, C2-H, C5-H and C6-H): MS (EI) m/z: 316 (M+). Anal. calcd 
for C17H14ClFN2O; C, 64.46; H, 4.45; Cl, 11.19; F, 6.00; N, 8.84; O, 5.05.
2h 6-(anthracen-9-yl)-4-(4-fluoro-3-methylphenyl)-1,6-dihydropyrimi 
dine-2-ol
Yield 70%, m.p. 171°C, FT-IR (KBr) cm−1: 1037.27 (C-F); 2922.80 (C-CH3 
Str); 2854.51 (C-H str) 1658.91 (C=N str); 1455 (Ar C=C); 3439.50 (NH 
str); 3739 (OH); 1HNMR(400 MHz, CDCl3, δ ppm) 2.382 (s, 3H, CH3); 
1.622 (s, 1H, O-H); 2.193 (m, 1H, N-H); 3.518 (d, J=5.6Hz, 1H, C6’-H 
pyrimidine); 7.173 (m, J=8.4Hz, 1H, C5’-H pyrimidine); 7.527-8.883 (m, 
9H, Anthracene-H); 7.999-7.932 (m, 3H, Ar-H): MS (EI) m/z: 382 (M+). 




Yield 73%, m.p. 160°C, FT-IR (KBr) cm−1: 1072 (C-F): 851 (C-Br): 
2928 (C-CH3 Str): 2926 (C-H str) 1607 (C=N str): 1399 (Ar C=C): 3421 
(NH str): 3562 (OH): 1223 (O-CH3); 1HNMR(400 MHz, CDCl3, δ ppm) 
2.49 (s, 3H, CH3); 1.798 (s, 1H, N-H); 2.052 (m, 1H, O-H); 3.89 (3H, 
OCH3); 4.519 (d, J=8.2Hz, 1H, C6’-H pyrimidine); 7.69 (1H, OH); 7.06 
(m, J=7.6Hz, 1H, C5’-H pyrimidine); 6.91 (1H, C4”-H); 7.55 (1H, C6”-H); 
7.22 (1H, C2-H); 7.29 (1H, C5-H); 7.91 (1H, C6-H): MS (EI) m/z: 407 (M+). 
Anal. calcd for C17H14ClFN2O; C, 53.09; H, 3.96; Br, 19.63; F, 4.67; N, 6.88; 
O, 11.79.
Anti-inflammatory activity
In vitro anti-inflammatory screening
The human red blood cell (HRBC) membrane stabilization method
The blood was collected from a healthy human volunteer and mixed with 
equal volume of Alsever solution (2% dextrose, 0.8% sodium citrate, 0.5% 
citric acid, and 0.42% NaCl) and centrifuged at 3000 rpm for 10 min. The 
packed cells were washed with iso-saline (0.36%) and a 10% suspension 
was made. Various concentrations of 4-(4-fluoro-3-methylphenyl)-6-
(substituted aryl)-1,6-dihydropyrimidin-2-ol (2a–2j) were prepared 
(75, 150, and 200 µg/ml) using distilled water and to each concentration 
1 ml of phosphate buffer, 2 ml hyposaline, and 0.5 ml of HRBC suspension 
were added. It was incubated at 37°C for 30 min and centrifuged at 
3000 rpm for 20 min, and the hemoglobin content of the supernatant 
solution was estimated spectrophotometrically at 560 nm. Diclofenac 
(75, 150, and 200 µg/ml) was used as the reference standard, and the 
control was prepared by omitting the compounds under examination.
The percentage of HRBC membrane stabilization or protection was 
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Ethical approval
All experiments have been examined and approved by the Institutional 
Animal Ethics Committee at the GITAM University, Visakhapatnam, 
India (Approved proposal No:- IAEC/GIP-1287/CAD-UGC/
approved/3/2015). Animal experiments were also performed in 
accordance with the Guidelines on Ethical Standards for Investigation 
of Experimental Pain in Animals [18].
In vivo anti-inflammatory activity
Wistar albino rats of either sex (200 – 250 gms) were procured from 
Ghosh Enterprises kolkatta, West Bengal. A total of 72 rats were 
divided into 12 groups of 6 rats each. They were allowed for fasting 
overnight and given water ad libitum. Group I was given only 1% 
sodium carboxymethyl cellulose suspension (1 ml/kg) and was used 
as carrageenan-treated control. Group II was treated with the standard 
drug diclofenac (100mg/kg). Similarly, the rest of the groups were 
administered with test drugs (2a–2i), respectively. The test drugs 
(100 mg/kg body weight) and the standard drugs (100 mg/kg body 
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weight) were administered orally with the help of the oral catheter. 
After 30 min, 0.05 ml of 1% carrageenan suspension was slowly 
injected subcutaneously into the subplantar region of the left hind paw 
to all the groups to produce inflammation. After the administration 
of carrageenan, the volume of its displacement was measured 
volumetrically by comparing with 0 min reading and again after every 
1, 2, 3, and 4 h of induction with plethysmometer apparatus and 
compared. The percentage increase of paw thickness was determined 
at 0, 1, 2, 3, and 4 h after induction of inflammation.








The acetic acid writhing test was performed on Wistar albino rats by 
following the method of Berkowitz et al. [19]. Test compounds were given 
to the animals at the dose of 50 mg/kg, 30 min later the animals have 
injected intraperitoneally with 0.25 ml/rat of 0.5% acetic acid. The mean 
number of writhes for each experimental groups and the percentage 
decrease compared with the control group was calculated after 60 min.
RESULTS AND DISCUSSION
The title compounds 2a-2i were synthesized as per the protocol shown 
in Scheme 1. In the present work, by substituting different aryl moiety at 
the C-6 position of 4-(4-fluoro-3-methylphenyl)-1,6-dihydropyrimidin-
2-ol, a sequence of novel pyrimidine derivatives 2a-2i was synthesized. 
The presence of particular groups was identified from IR spectra by 
means of some characteristic absorption bands. The IR spectrum of 
chalcones showed characteristic intense absorption bands at 1657 
(C=O, chalcone), 1585 (C=C), 1149 (C-Fl), and 2949 (C-CH3). The 
formation of pyrimidine was confirmed from the absorption bands of 
IR spectra. The absorption band at 3449.10 indicates NH Stretch of 
the pyrimidine ring. Further, it can also be confirmed from the1H NMR 
spectral data. A strong peak at δ 1.593 ppm integrating for N-H proton 
of pyrimidines. The spectrum also revealed a doublet at δ 2.194 ppm for 
the proton of C-6-H of the pyrimidine ring. A singlet peak at δ 2.34 ppm 
for three protons which might be assigned to CH3. The structure of title 
compounds 2a–2i was further confirmed by the appearance of various 
other peaks in NMR spectroscopy corresponding to the assigned 
structure. In addition, the data of the mass spectrum further confirmed 
their molecular weight and purity.
Biological activities
In vitro anti-inflammatory activity (HRBC membrane stabilization 
method)
In vitro anti-inflammatory activity of test compounds was evaluated 
using the HRBC membrane stabilization method. The anti-inflammatory 
activity results (Table 1) revealed that all the test compounds showed 
better activity when compared to that of standard drug. From the 
results, it was observed that the compounds 2g and 2b exhibited 
good activity when compared to that of standard drug. It may be 
due to the presence of halogen group on the phenyl ring attached at 
position-6 of pyrimidine. The compound 2i also showed good activity. 
The presence of bulk anthracene group attached to the pyrimidine ring 
may contribute to its activity. The compound 2a with thiophene moiety 
attached to the pyrimidine ring also showed good activity. Rest of the 
compounds showed moderate anti-inflammatory activity.
In vivo anti-inflammatory activity (carrageenan-induced rat paw 
edema method)
In vivo anti-inflammatory activity of test compounds was evaluated using 
carrageenan-induced rat paw edema method. The anti-inflammatory 
activity results (Table 2) revealed that all the test compounds showed 
better activity when compared to that of standard drug. The phenyl ring 
substituted with hydroxyl, methoxy, and nitro substituents attached 
at position-6 of pyrimidine causes a decrease in the activity of the 
compound 2d. The compound 2e possessing dimethoxyphenyl ring at 
position-6 of pyrimidine ring exhibited moderate anti-inflammatory 
activity when compared to the reference standard diclofenac sodium. 
Replacement of dimethoxy phenyl ring with 5-bromo-2-hydroxy-
3-methoxy phenyl ring 2i leads to an increase in the activity. With 
increased lipophilicity, the compound with dimethylamino substituent 
2f and nitrophenyl substituents 2c showed the least activity. Among 
all tested compounds para chloro analog 2g exhibited a better activity 
which was more potent than diclofenac. Compounds with anthracene 
moiety 2h, 2-bromo phenyl 2b and thiophene ring 2a also showed 
better activity.
Analgesic activity
Entire test compounds 2a–2i were tested for their analgesic activity 
by the tail-flick technique using Wistar albino mice. The results of 
the analgesic study were summarized in Table 2. Compounds 2g with 
4-chlorophenyl derivative and 2b with 2-bromophenyl derivative 
showed similar analgesic activity compared to standard drug diclofenac 
sodium. Replacement of chlorine group with nitro or dimethylamino 
or methoxy or hydroxyl groups results in a sharp fall in the activity. 
It may be due to a decrease in the lipophilicity. From the results, it 
was found that the pyrimidine derivatives with halogen substituents 
showed better activity when compared to other derivatives. 
Compounds 6-(4-chlorophenyl)-4-(4-fluoro-3-methylphenyl)-1,6-
dihydropyrimidin-2-ol 2g and 4-(4-fluoro -3-methylphenyl)-6-(2-
bromo phenyl)-1,6-dihydropyrimidin-2-ol 2b were found to be the most 
active analgesic agent and it showed similar potency when compared to 
the reference standard diclofenac sodium.
CONCLUSION
In summary, a series of novel pyrimidine derivatives 2a–2i were 
synthesized and characterized by FT-IR, 1H-NMR, mass spectroscopy, and 
elemental analysis. These derivatives were evaluated for their analgesic 
Table 1. Anti-inflammatory activity of pyrimidine (2a–2i) HRBC 
method
S.No Compound Concentration (µg/ml) %Stabilization
1. 2a 75 50.21
150 69.12
200 80.16
2. 2b 75 49.84
150 58.12
200 82.56
3. 2c 75 39.06
150 55.15
200 71.46
4. 2d 75 41.65
150 55.51
200 65.23
5. 2e 75 44.61
150 56.18
200 76.35
6. 2f 75 46.54
150 54.21
200 64.11
7. 2g 75 51.17
150 64.25
200 91.12
8. 2h 75 46.93
150 61.62
200 74.45
9. 2i 75 49.44
150 66.16
200 88.61
10. Diclofenac 75 64.26
150 78.74
200 94.67
HRBC: Human red blood cell
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and anti-inflammatory activities. In general, chlorine substituted 
compounds exhibited potent analgesic and anti-inflammatory activities. 
From the study, it was concluded that in this series nature of the substituent 
played a major role in analgesic and anti-inflammatory activity than its 
position. Among several tested compounds, 6-(4-chlorophenyl)-4-(4-
fluoro-3-methylphenyl)-1,6-dihydro pyrimidin-2-ol 2g showed better 
analgesic and anti-inflammatory activities which were more potent than 
reference standard diclofenac. Hence, this analog could be developed as 
a new class of analgesic and anti-inflammatory agent.
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